Changing paradigms in antiplatelet therapy after coronary intervention

Affiliations

Editorial

Patrick Sulzgruber. Eur Heart J Cardiovasc Pharmacother. 2021.

. 2021 May 23;7(3):206-208.

doi: 10.1093/ehjcvp/pvaa043.

¹ Department of Medicine II, Division of Cardiology, Medical University of Vienna, Austria.

No abstract available

Comment on

P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients.
Bianco M, Careggio A, Destefanis P, Luciano A, Perrelli MG, Quadri G, Rossini R, Campo G, Vizzari G, D'Ascenzo F, Anselmino M, Biondi-Zoccai G, Ibáñez B, Montagna L, Varbella F, Cerrato E. Bianco M, et al. Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):196-205. doi: 10.1093/ehjcvp/pvaa038. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32544220